» Articles » PMID: 32730619

Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19)

Abstract

Importance: Coronavirus disease 2019 (COVID-19) continues to cause considerable morbidity and mortality worldwide. Case reports of hospitalized patients suggest that COVID-19 prominently affects the cardiovascular system, but the overall impact remains unknown.

Objective: To evaluate the presence of myocardial injury in unselected patients recently recovered from COVID-19 illness.

Design, Setting, And Participants: In this prospective observational cohort study, 100 patients recently recovered from COVID-19 illness were identified from the University Hospital Frankfurt COVID-19 Registry between April and June 2020.

Exposure: Recent recovery from severe acute respiratory syndrome coronavirus 2 infection, as determined by reverse transcription-polymerase chain reaction on swab test of the upper respiratory tract.

Main Outcomes And Measures: Demographic characteristics, cardiac blood markers, and cardiovascular magnetic resonance (CMR) imaging were obtained. Comparisons were made with age-matched and sex-matched control groups of healthy volunteers (n = 50) and risk factor-matched patients (n = 57).

Results: Of the 100 included patients, 53 (53%) were male, and the mean (SD) age was 49 (14) years. The median (IQR) time interval between COVID-19 diagnosis and CMR was 71 (64-92) days. Of the 100 patients recently recovered from COVID-19, 67 (67%) recovered at home, while 33 (33%) required hospitalization. At the time of CMR, high-sensitivity troponin T (hsTnT) was detectable (greater than 3 pg/mL) in 71 patients recently recovered from COVID-19 (71%) and significantly elevated (greater than 13.9 pg/mL) in 5 patients (5%). Compared with healthy controls and risk factor-matched controls, patients recently recovered from COVID-19 had lower left ventricular ejection fraction, higher left ventricle volumes, and raised native T1 and T2. A total of 78 patients recently recovered from COVID-19 (78%) had abnormal CMR findings, including raised myocardial native T1 (n = 73), raised myocardial native T2 (n = 60), myocardial late gadolinium enhancement (n = 32), or pericardial enhancement (n = 22). There was a small but significant difference between patients who recovered at home vs in the hospital for native T1 mapping (median [IQR], 1119 [1092-1150] ms vs 1141 [1121-1175] ms; P = .008) and hsTnT (4.2 [3.0-5.9] pg/dL vs 6.3 [3.4-7.9] pg/dL; P = .002) but not for native T2 mapping. None of these measures were correlated with time from COVID-19 diagnosis (native T1: r = 0.07; P = .47; native T2: r = 0.14; P = .15; hsTnT: r = -0.07; P = .50). High-sensitivity troponin T was significantly correlated with native T1 mapping (r = 0.33; P < .001) and native T2 mapping (r = 0.18; P = .01). Endomyocardial biopsy in patients with severe findings revealed active lymphocytic inflammation. Native T1 and T2 were the measures with the best discriminatory ability to detect COVID-19-related myocardial pathology.

Conclusions And Relevance: In this study of a cohort of German patients recently recovered from COVID-19 infection, CMR revealed cardiac involvement in 78 patients (78%) and ongoing myocardial inflammation in 60 patients (60%), independent of preexisting conditions, severity and overall course of the acute illness, and time from the original diagnosis. These findings indicate the need for ongoing investigation of the long-term cardiovascular consequences of COVID-19.

Citing Articles

Comparing myocardial injury patterns and outcomes in cardiac magnetic resonance imaging between COVID-19- and non-COVID-19-related myocarditis.

Hajsadeghi S, Kasaei M, Pouraliakbar H, Jamalkhani S, Mirshafiee S Pol J Radiol. 2025; 90:e36-e45.

PMID: 40070417 PMC: 11891549. DOI: 10.5114/pjr/199445.


mTORC1 syndrome (TorS): unifying paradigm for PASC, ME/CFS and PAIS.

Bar-Tana J J Transl Med. 2025; 23(1):297.

PMID: 40059164 PMC: 11892318. DOI: 10.1186/s12967-025-06220-z.


Assessing the impact of COmorbidities and Sociodemographic factors on Multiorgan Injury following COVID-19: rationale and protocol design of COSMIC, a UK multicentre observational study of COVID-negative controls.

Shergill S, Elshibly M, Hothi S, Parke K, England R, Wormleighton J BMJ Open. 2025; 15(3):e089508.

PMID: 40050066 PMC: 11887317. DOI: 10.1136/bmjopen-2024-089508.


Echocardiographic Left Ventricular Function in the Third Year After COVID-19 Hospitalization: A Follow-Up Pilot Study in South-East of Romania.

Vlase C, Gutu C, Bogdan Goroftei R, Boghean A, Iordachi T, Arbune A Medicina (Kaunas). 2025; 61(2).

PMID: 40005449 PMC: 11857121. DOI: 10.3390/medicina61020333.


Genetic and Epigenetic Intersections in COVID-19-Associated Cardiovascular Disease: Emerging Insights and Future Directions.

Sabit H, Arneth B, Altrawy A, Ghazy A, Abdelazeem R, Adel A Biomedicines. 2025; 13(2).

PMID: 40002898 PMC: 11852909. DOI: 10.3390/biomedicines13020485.


References
1.
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C . Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4):420-422. PMC: 7164771. DOI: 10.1016/S2213-2600(20)30076-X. View

2.
Guo T, Fan Y, Chen M, Wu X, Zhang L, He T . Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020; 5(7):811-818. PMC: 7101506. DOI: 10.1001/jamacardio.2020.1017. View

3.
Varga Z, Flammer A, Steiger P, Haberecker M, Andermatt R, Zinkernagel A . Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020; 395(10234):1417-1418. PMC: 7172722. DOI: 10.1016/S0140-6736(20)30937-5. View

4.
Wei X, Fang Y, Hu H . Glucocorticoid and immunoglobulin to treat viral fulminant myocarditis. Eur Heart J. 2020; 41(22):2122. PMC: 7279514. DOI: 10.1093/eurheartj/ehaa357. View

5.
Rogers T, Dabir D, Mahmoud I, Voigt T, Schaeffter T, Nagel E . Standardization of T1 measurements with MOLLI in differentiation between health and disease--the ConSept study. J Cardiovasc Magn Reson. 2013; 15:78. PMC: 3847466. DOI: 10.1186/1532-429X-15-78. View